TNYA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.7M
+52.9%
1.1M
+393.3%
225.0K
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
1.7M
+52.9%
1.1M
+393.3%
225.0K
0
0
Operating Expenses
21.2M
-51.7%
43.8M
+116.0%
20.3M
-2.3%
20.8M
-0.8%
20.9M
R&D
14.9M
-10.5%
16.6M
+11.9%
14.8M
+0.3%
14.8M
-3.7%
15.4M
SG&A
5.6M
+4.5%
5.4M
-0.8%
5.4M
-8.9%
6.0M
+7.2%
5.6M
Operating Income
-19483000
+54.4%
-42720000
-112.9%
-20065000
+3.4%
-20775000
+0.8%
-20936000
EBITDA
-18423000
+4.1%
-19201000
-4.9%
-18302000
+3.4%
-18948000
+0.7%
-19072000
Net Income
-18938000
+56.4%
-43393000
-125.2%
-19272000
+4.5%
-20175000
+0.5%
-20275000
EPS (Basic)
$-0.08
+60.0%
$-0.20
-122.2%
$-0.09
+18.2%
$-0.11
+8.3%
$-0.12
EPS (Diluted)
$-0.08
+60.0%
$-0.20
-122.2%
$-0.09
+18.2%
$-0.11
+8.3%
$-0.12
Shares (Diluted)
226.0M
+3.9%
217.6M
+0.3%
216.9M
+23.3%
175.9M
+7.7%
163.3M
Tenaya Therapeutics (TNYA) — Financials